← Back to all trials
Active Not Recruiting
NCT07107373
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 150
Sponsor: Bristol-Myers Squibb
Location: University of California, San Francisco (UCSF) San Francisco California
Summary
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years at the index date
* Prescription of mavacamten for the treatment of Obstructive hypertrophic cardiomyopathy (oHCM) with NYHA Class II or III
* ≥ 12 weeks of follow-up after prescription of mavacamten, except for the baseline data reporting
Exclusion Criteria:
* Data collection as part of a clinical trial during the study period
* Participation in a myosin inhibitor clinical trial
Source: ClinicalTrials.gov (NCT07107373). StuddyBuddy aggregates publicly available trial information.
